Hannah Woriax

Hannah Woriax

Auto-generated profile, based on publicly available information

Hannah Woriax

Duke Univ, Dept Surg, DUMC 3513, Durham, NC 27710 USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Annals of Surgery
Verified
Journal Article
Closed access
RMRita A. Mukhtar
Rita A. Mukhtar
HCHarrison Chau
Harrison Chau
HWHannah Woriax
Hannah Woriax
MPMara D.O. Piltin
Mara D.O. Piltin
GAGretchen M.D Ahrendt
Gretchen M.D Ahrendt
JBJudy C. Boughey
Judy C. Boughey
Neoadjuvant chemotherapy (NAC) increases rates of successful breast-conserving surgery (BCS) in patients with breast cancer. However, some studies suggest that BCS after NAC may confer an increased risk of locoregional recurrence (LRR). We assessed LRR rates and locoregional recurrence-free survival (LRFS) in patients enrolled on I-SPY2 (NCT01042379), a prospective NAC trial for patients with clinical stage II to III, molecularly high-risk breast cancer. Cox proportional hazards models were used to evaluate associations between surgical procedure (BCS vs mastectomy) and LRFS adjusted for age, tumor receptor subtype, clinical T category, clinical nodal status, and residual cancer burden (RCB). In 1462 patients, surgical procedure was not associated with LRR or LRFS on either univariate or multivariate analysis. The unadjusted incidence of LRR was 5.4% after BCS and 7.0% after mastectomy, at a median follow-up time of 3.5 years. The strongest predictor of LRR was RCB class, with each increasing RCB class having a significantly higher hazard ratio for LRR compared with RCB 0 on multivariate analysis. Triple-negative receptor subtype was also associated with an increased risk of LRR (hazard ratio: 2.91, 95% CI: 1.8–4.6, P < 0.0001), regardless of the type of operation. In this large multi-institutional prospective trial of patients completing NAC, we found no increased risk of LRR or differences in LRFS after BCS compared with mastectomy. Tumor receptor subtype and extent of residual disease after NAC were significantly associated with recurrence. These data demonstrate that BCS can be an excellent surgical option after NAC for appropriately selected patients.

6 February 2024 in The American Journal of Surgery
Verified
Journal Article
Closed access
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
MPMorgan A. Paul
Morgan A. Paul
STSamantha M Thomas
Samantha M Thomas
SSSarah L. Sammons
Sarah L. Sammons
MDMaggie L. DiNome
Maggie L. DiNome
EHE Shelley Hwang
E Shelley Hwang